RxDoctor Payments Data

Kelleigh Sorenson

Family · Paso Robles, CANPI 1376282178

Payments from drug & device makers

$1,400in general payments, 2019–2025

Across 37 payments — averaging $37.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$666
  • AbbVie$242
  • Novo Nordisk$186
  • Astellas Pharma US Inc$129
  • Pfizer$46
  • Boehringer Ingelheim$44
  • plus $85 from 4 others

What the payments were for

  • Food & beverage$1,30093%
  • Education$1007%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,400 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$41,047
Medicare patients
147
Services billed
530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide43$56,029
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$34,555
MounjaroTirzepatide22$20,347
OzempicSemaglutide15$16,749
EliquisApixaban20$12,690
Breo ElliptaFluticasone/Vilanterol14$5,608
Liothyronine Sodium60$2,573
SynthroidLevothyroxine Sodium19$2,088
Levothyroxine Sodium122$1,866
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,811
Duloxetine Hcl43$1,726
Atorvastatin Calcium84$1,095
Clonidine16$763
Rosuvastatin Calcium37$756
Nano 2nd Gen Pen NeedlePen Needle, Diabetic12$718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$28$76,37665 claims
GSKTrelegy Ellipta, Breo Ellipta$666$40,16348 claims
Novo NordiskOzempic$186$16,74915 claims
PfizerEliquis$46$12,69020 claims
AbbVieSynthroid$242$2,08819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.

Other family in Paso Robles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →